[Effect of combination therapy with preduktal and prestarium on the left ventricular function in the postinfarction period].
The aim of the study was to estimate the efficiency of combination therapy with Preductal and Prestarium after MI. We investigated 152 patients with acute MI of anterior wall (Q wave) and Heart Failure (II-III class by NYHA). I group included 92 p, which were treated by Preductal (60 mg daily) on the background of the standard therapy. II group (60 p) treated by standard therapy. (ACE inhibitor, diuretic, beta-blocks). We divided the patients in 2 subgroups, with EF>45% and EF<45%. Echo investigation was performed after 1,3,6.12 months from the beginning of MI. We estimated LV EDV and ESV, EF, FS, SV and diastolic function. 12 month after myocardial infarction decreases of average heart failure and angina classes. After 6,12 months was noted decreased EDV and ESV, increased EF, FS,SV in both groups confidence, but spatially in the I gr. Patients, who had EF<45% and were treated with Preductal improved EF with 30,1%(p<0,05) confidence, which was 1,5 times more then in the control gr, also increased FS and SV by 32,7%, 13,6% p<0,05. At the same time was observed diastolic function improvement, particular decreased Ve, Ve/Va, and increased Va specially in the Preductal group more intensive and confidence. The treatment with Preductal during 12 months indicates his positive influence on the LV systolic and diastolic function, which is most significant in the patients with low EF.
Dzhindzholiia
N R
NR
Megreladze
I I
II
D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000175:diagnosis* / Q000188:drug therapy*; D020913:Perindopril / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D014292:Trimetazidine / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D016277:Ventricular Function, Left / Q000187:drug effects*
D000806:Angiotensin-Converting Enzyme Inhibitors; D014665:Vasodilator Agents; D014292:Trimetazidine; D020913:Perindopril